Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
However, SBRT may not be enough for people with intermediate-risk prostate cancer and unfavorable genetic features. These features may make it more likely that the cancer will come back after radiation therapy. These people may benefit from SBRT with hormonal therapy early in their care.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Women with a mutation in the BRCA1 or BRCA2 genes are at increased risk for hereditary breast and ovarian cancer. However, the cancer risk estimates for these gene mutations are currently wide-ranging and non-specific. A new form of genetic testing, called "genetic risk modifier testing," may give women with BRCA1/2 gene mutations more specific estimates of their risk of developing breast cancer.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are comparing bone marrow transplantation to maintenance chemotherapy as post-induction treatment in older people with acute myeloid leukemia (AML) in remission. The people in this study are 65 or older and already had azacitidine and venetoclax as induction treatment.
The purpose of this study is to find the highest dose of the investigational drug PF-07799933 that can be given alone and in combination with binimetinib or cetuximab in people with advanced solid tumors that have continued to grow despite treatment and contain a mutation in the BRAF gene. A mutated BRAF gene makes a protein that sends signals to cancer cells to grow and divide. While some anti-cancer drugs only work for certain BRAF mutations, the investigational drug PF-07799933 may target all types of BRAF mutant proteins, blocking them from sending these signals and causing cancer cells to die.
The purpose of this study is to assess the safety and effectiveness of the drug mosunetuzumab for people with follicular lymphoma who have not yet received treatment. Mosunetuzumab binds to a cancer cell and a T cell (which plays a key role in the immune system) at the same time. Researchers think that mosunetuzumab may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. Mosunetuzumab is given as a subcutaneous (under the skin) injection.
The purpose of this study is to find the best dose of AZD0120 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.
Breast cancer (TNBC) and non-small cell lung cancer (NSCLC) that spread to other parts of the body (metastasize) are usually treated with chemotherapy, immunotherapy, targeted therapies, and/or radiation therapy. In this study, researchers want to see if using stereotactic body radiosurgery (SBRT) to all metastatic tumors plus standard therapy is more effective than standard therapy alone in patients with oligometastatic TNBC or NSCLC (five or fewer metastatic tumors).
